Suvretta reports 7.7% stake in Lexeo Therapeutics

Lexeo Therapeutics ownership disclosure: Suvretta Capital Management, LLC reports shared beneficial ownership of 5,674,778 shares (7.7%) of common stock, and Averill Master Fund, Ltd. reports shared beneficial ownership of 4,827,730 shares (6.5%).

Rhea-AI Filing Summary

Lexeo Therapeutics ownership disclosure: Suvretta Capital Management, LLC reports shared beneficial ownership of 5,674,778 shares (7.7%) of common stock, and Averill Master Fund, Ltd. reports shared beneficial ownership of 4,827,730 shares (6.5%). Aaron Cowen is reported with shared beneficial ownership of 5,674,778 shares (7.7%). The schedule states these securities are directly owned by advisory clients of Suvretta and includes a joint filing agreement and control-person identification.

Insights

Institutional Ownership Analyst

Large passive holdings disclosed by an investment adviser and an affiliated fund.

Su v retta Capital and Averill Master Fund are reported as holding 5,674,778 and 4,827,730 shares respectively, representing 7.7% and 6.5% of the class. The holdings are shown as shared voting and shared dispositive power.

The filing notes the shares are held for advisory clients and includes a joint filing agreement and an exhibit identifying the control person. Subsequent SEC schedules could show changes if these advisory clients alter positions.

Corporate Governance Specialist

Reporting emphasizes shared authority and advisory-client ownership.

The schedule discloses zero sole voting or dispositive power and records shared powers for voting and disposition, which signals control via advisory arrangements rather than direct individual ownership. A signed disclaimer accompanies the filing.

Watch for any amendments that change classification (e.g., Schedule 13D) or disclose additional parties named in Exhibit B; timing for such updates is not stated here.

Key Figures

Suvretta shares reported: 5,674,778 shares Averill shares reported: 4,827,730 shares Percent of class (Suvretta/Cowen): 7.7% +1 more

4 metrics

Suvretta shares reported 5,674,778 shares shared beneficial ownership reported on Schedule 13G

Averill shares reported 4,827,730 shares shared beneficial ownership reported on Schedule 13G

Percent of class (Suvretta/Cowen) 7.7% percent of common stock reported for Suvretta Capital and Aaron Cowen

Percent of class (Averill) 6.5% percent of common stock reported for Averill Master Fund, Ltd.

Key Terms

shared dispositive power, beneficial ownership, Joint Filing Agreement, control person identification

4 terms

shared dispositive power regulatory

"Shared Dispositive Power 5,674,778.00"

beneficial ownership regulatory

"Amount beneficially owned: Suvretta Capital Management, LLC - 5,674,778"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Joint Filing Agreement legal

"Exhibit A - Joint Filing Agreement"

control person identification legal

"Exhibit B - Control Person Identification"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Suvretta Capital hold in Lexeo Therapeutics (LXEO)?

Suvretta Capital is reported with shared beneficial ownership of 5,674,778 shares, representing 7.7% of Lexeo Therapeutics' common stock. The filing states these shares are owned by advisory clients of Suvretta.

How much does Averill Master Fund, Ltd. own of LXEO?

Averill Master Fund, Ltd. is reported with shared beneficial ownership of 4,827,730 shares, equal to 6.5% of the class. The filing lists the fund as a Cayman Islands-registered entity.

Does Aaron Cowen personally own the reported LXEO shares?

Aaron Cowen is shown with shared beneficial ownership of 5,674,778 shares (7.7%). The filing includes a disclaimer stating reporting persons disclaim beneficial ownership except to the extent of pecuniary interest.

Are the reported holdings sole or shared voting power for LXEO shares?

The schedule reports 0 shares of sole voting power and shared voting and dispositive power for the reported amounts: 5,674,778 (Suvretta/Cowen) and 4,827,730 (Averill).

What exhibits accompany this Schedule 13G filing for LXEO?

The filing includes Exhibit A (Joint Filing Agreement) and Exhibit B (Control Person Identification). Signatures are provided by authorized signatories and Aaron Cowen.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/13/2026 - 05:03 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Lexeo Therapeutics, Inc.

(Name of Issuer)

Common stock, par value $0.0001

(Title of Class of Securities)

52886X107

(CUSIP Number)

04/06/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 52886X107

1

Names of Reporting Persons

SUVRETTA CAPITAL MANAGEMENT, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,674,778.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,674,778.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,674,778.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.7 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 52886X107

1

Names of Reporting Persons

Averill Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,827,730.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,827,730.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,827,730.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.5 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 52886X107

1

Names of Reporting Persons

AARON COWEN

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,674,778.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,674,778.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,674,778.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.7 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Lexeo Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 345 Park Avenue South, Floor 6, New York, NY, 10010
Item 2.
(a)	Name of person filing: Suvretta Capital Management, LLC Averill Master Fund, Ltd. Aaron Cowen
(b)	Address or principal business office or, if none, residence: Suvretta Capital Management, LLC 540 Madison Avenue, 7th Floor New York, New York 10022 United States of America Averill Master Fund, Ltd. c/o Maples Corporate Services Limited P.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Aaron Cowen c/o Suvretta Capital Management, LLC 540 Madison Avenue, 7th Floor New York, New York 10022
(c)	Citizenship: Suvretta Capital Management, LLC - Delaware Averill Master Fund, Ltd. - Cayman Islands Aaron Cowen - United States
(d)	Title of class of securities: Common stock, par value $0.0001
(e)	CUSIP Number(s): 52886X107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Suvretta Capital Management, LLC - 5,674,778 Averill Master Fund, Ltd. - 4,827,730 Aaron Cowen - 5,674,778
(b)	Percent of class: Suvretta Capital Management, LLC - 7.7% Averill Master Fund, Ltd. - 6.5% Aaron Cowen - 7.7%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Suvretta Capital Management, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0
	(ii) Shared power to vote or to direct the vote: Suvretta Capital Management, LLC - 5,674,778 Averill Master Fund, Ltd. - 4,827,730 Aaron Cowen - 5,674,778
	(iii) Sole power to dispose or to direct the disposition of: Suvretta Capital Management, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0
	(iv) Shared power to dispose or to direct the disposition of: Suvretta Capital Management, LLC - 5,674,778 Averill Master Fund, Ltd. - 4,827,730 Aaron Cowen - 5,674,778
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. All of the securities reported in this Schedule 13G are directly owned by advisory clients of Suvretta Capital Management, LLC. None of those advisory clients, other than Averill Master Fund, Ltd., may be deemed to beneficially own more than 5% of the Common stock, $0.0001 par value.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Please see Exhibit B attached hereto.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SUVRETTA CAPITAL MANAGEMENT, LLC

Signature:	By: /s/ Andrew Nathanson
Name/Title:	Andrew Nathanson, General Counsel and Chief Compliance Officer
Date:	04/13/2026

Averill Master Fund, Ltd.

Signature:	By: /s/ Andrew Nathanson
Name/Title:	Andrew Nathanson, Authorized Signatory
Date:	04/13/2026

AARON COWEN

Signature:	By: /s/ Aaron Cowen
Name/Title:	Aaron Cowen
Date:	04/13/2026

Comments accompanying signature: * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.

Exhibit Information

Exhibit A - Joint Filing Agreement Exhibit B - Control Person Identification